JP2014196341A - 免疫源性ペプチドの標的特異的同定方法 - Google Patents
免疫源性ペプチドの標的特異的同定方法 Download PDFInfo
- Publication number
- JP2014196341A JP2014196341A JP2014136512A JP2014136512A JP2014196341A JP 2014196341 A JP2014196341 A JP 2014196341A JP 2014136512 A JP2014136512 A JP 2014136512A JP 2014136512 A JP2014136512 A JP 2014136512A JP 2014196341 A JP2014196341 A JP 2014196341A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- peptide
- immunogenic
- sequence
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Abstract
【解決手段】自己タンパク質からの免疫原性ペプチドの合成方法であって、抗体結合と直接的若しくは間接的に関与する自己タンパク質中の1つ以上のペプチド配列を同定するステップと、上記1つ以上のペプチド配列を、免疫原性を有すると予想される配列を同定するためのアルゴリズムを用いて解析するステップと、上記1つ以上のペプチド配列からの全てのペプチド断片をスクリーニングするステップと、上記タンパク質断片中の免疫原性ペプチドを同定するステップを含んでなる方法。上記の抗体結合相互作用はポリクローナル性であってもよく、またモノクローナル性であってもよい。
【選択図】なし
Description
Claims (26)
- 自己タンパク質から少なくとも1つの免疫原性ペプチドを合成するin vitroの方法であって、
前記少なくとも1つの免疫原性ペプチドは抗体との結合相互作用に関与し、
前記方法は、
未使用かつ免疫反応性を有するT細胞のプールにより認識される自己タンパク質のタンパク質断片を同定するステップと、
前記タンパク質断片を、抗体結合相互作用に関与するペプチド配列を同定するアルゴリズムにより解析するステップと、
前記タンパク質断片中に存在する、免疫原性を有し、抗体結合相互作用に関与する1つ以上のペプチド配列を同定するステップと、
抗体結合相互作用に関与する前記1つ以上のペプチド配列に対応する少なくとも1つの免疫原性ペプチドを合成するステップであって、前記少なくとも1つの免疫原性ペプチドは前記抗体との併用療法で用いられるステップを含んでなる方法。 - タンパク質と結合する抗体を産生させることを更に含んでなる、請求項1記載の方法。
- 抗体との併用療法で使用するための、請求項1記載の方法により同定される前記抗体との結合相互作用に関与する免疫原性ペプチド。
- 請求項3記載の免疫原性ペプチドを含有するワクチン。
- 請求項4記載の免疫原性ペプチドと反応する抗体を更に含有する請求項4記載のワクチン。
- 前記自己タンパク質は、HER−2/neuタンパク質である請求項1記載の方法。
- 治療的に有効な組成物であって、Her2/neu抗原の配列の一部を示し、配列番号:2(E75=KIFGSLAFL)の配列を含むペプチドを含み、更に、前記抗原の免疫原性領域に結合する抗体を含む組成物。
- 前記ペプチドの配列は、実質的に前記抗体の結合部位の免疫原性領域内である請求項7記載の組成物。
- 前記抗体はトラスツズマブである請求項8に記載の組成物。
- 請求項9記載の組成物を含むワクチンであって、癌治療に治療効果のあるワクチン。
- 前記癌は乳癌である請求項10記載のワクチン。
- 癌治療に用いられる医薬組成物であって、Her2/neu抗原の配列の一部を示すペプチドを含み、前記ペプチドは配列番号:2(E75=KIFGSLAFL)の配列を含み、更に、前記抗原の免疫原性領域に結合する抗体を含み、前記抗体はトラスツズマブである医薬組成物。
- 患者を治療する方法であって、以下の工程(ただし工程の順序は問わない)を含む方法。
(a)治療的有効量の抗体を前記患者に投与する工程であって、前記抗体はトラスツズマブである工程、及び
(b)治療的有効量のペプチドを前記患者に投与する工程であって、前記ペプチドはHer2/neu抗原の配列の一部を示し、配列番号:2(E75=KIFGSLAFL)の配列を含む工程。 - 前記ペプチドは、前記抗体の投与前又は投与後又は投与と同時に投与される請求項13記載の方法。
- 前記ペプチドの投与及び前記抗体の投与は、前記患者に対し相乗効果を有する請求項14記載の方法。
- 前記患者は乳癌患者である請求項15記載の方法。
- 治療的に有効な組成物であって、Her2/neu抗原の配列の一部を示し、配列番号:17(GP2=IISAVVGIL)又は配列番号:18(GP2’=IVSAVVGIL)の配列を含むペプチドを含み、更に、前記抗原の免疫原性領域に結合する抗体を含む組成物。
- 前記ペプチドの配列は、実質的に前記抗体の結合部位の免疫原性領域内である請求項17記載の組成物。
- 前記抗体はトラスツズマブである請求項18記載の組成物。
- 請求項19記載の組成物を含むワクチンであって、癌治療に治療効果のあるワクチン。
- 前記癌は乳癌である請求項20記載のワクチン。
- 癌治療に用いられる医薬組成物であって、Her2/neu抗原の配列の一部を示すペプチドを含み、前記ペプチドは配列番号:17(GP2=IISAVVGIL)又は配列番号:18(GP2’=IVSAVVGIL)の配列を含み、更に、前記抗原の免疫原性領域に結合する抗体を含み、前記抗体はトラスツズマブである医薬組成物。
- 患者を治療する方法であって、以下の工程(ただし工程の順序は問わない)を含む方法。
(a)治療的有効量の抗体を前記患者に投与する工程であって、前記抗体はトラスツズマブである工程、及び
(b)治療的有効量のペプチドを前記患者に投与する工程であって、前記ペプチドはHer2/neu抗原の配列の一部を示し、配列番号:17(GP2=IISAVVGIL)又は配列番号:18(GP2’=IVSAVVGIL)の配列を含む工程。 - 前記ペプチドは、前記抗体の投与前又は投与後又は投与と同時に投与される請求項23記載の方法。
- 前記ペプチドの投与及び前記抗体の投与は、前記患者に対し相乗効果を有する請求項24記載の方法。
- 前記患者は乳癌患者である請求項25記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71486505P | 2005-09-08 | 2005-09-08 | |
US60/714,865 | 2005-09-08 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011255687A Division JP2012072167A (ja) | 2005-09-08 | 2011-11-24 | 免疫源性ペプチドの標的特異的同定方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016216370A Division JP2017043630A (ja) | 2005-09-08 | 2016-11-04 | 免疫源性ペプチドの標的特異的同定方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2014196341A true JP2014196341A (ja) | 2014-10-16 |
Family
ID=37836547
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008530244A Active JP5424640B2 (ja) | 2005-09-08 | 2006-09-08 | 免疫源性ペプチドの標的特異的同定方法 |
JP2011255687A Pending JP2012072167A (ja) | 2005-09-08 | 2011-11-24 | 免疫源性ペプチドの標的特異的同定方法 |
JP2014136512A Pending JP2014196341A (ja) | 2005-09-08 | 2014-07-02 | 免疫源性ペプチドの標的特異的同定方法 |
JP2016216370A Pending JP2017043630A (ja) | 2005-09-08 | 2016-11-04 | 免疫源性ペプチドの標的特異的同定方法 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008530244A Active JP5424640B2 (ja) | 2005-09-08 | 2006-09-08 | 免疫源性ペプチドの標的特異的同定方法 |
JP2011255687A Pending JP2012072167A (ja) | 2005-09-08 | 2011-11-24 | 免疫源性ペプチドの標的特異的同定方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016216370A Pending JP2017043630A (ja) | 2005-09-08 | 2016-11-04 | 免疫源性ペプチドの標的特異的同定方法 |
Country Status (5)
Country | Link |
---|---|
EP (2) | EP3195877A1 (ja) |
JP (4) | JP5424640B2 (ja) |
CA (3) | CA2812794C (ja) |
ES (1) | ES2628308T3 (ja) |
WO (1) | WO2007030771A2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5424640B2 (ja) * | 2005-09-08 | 2014-02-26 | ザ ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン,インコーポレイティド | 免疫源性ペプチドの標的特異的同定方法 |
EP2364366B1 (en) | 2008-11-05 | 2014-01-08 | MorphoSys AG | Deconvolution method |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005007694A1 (ja) * | 2003-07-16 | 2005-01-27 | Green Peptide Co., Ltd. | HER2/neuペプチドおよびその治療上の用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
ATE466869T1 (de) * | 1993-03-05 | 2010-05-15 | Epimmune Inc | Verfahren zur herstellung von immunogenen hla- a2.1-bindenden peptiden |
US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
US5550214A (en) * | 1994-02-10 | 1996-08-27 | Brigham And Women's Hospital | Isolated antigenic oncogene peptide fragments and uses |
US6780598B1 (en) | 1997-06-13 | 2004-08-24 | William J. Kokolus | Method of identifying and locating immunobiologically-active linear peptides |
US20040121946A9 (en) * | 2000-12-11 | 2004-06-24 | John Fikes | Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions |
JP4284490B2 (ja) * | 2001-07-16 | 2009-06-24 | 大塚製薬株式会社 | erbB−2関連ペプチド |
US7179645B2 (en) * | 2002-09-24 | 2007-02-20 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
AU2003285999A1 (en) * | 2002-12-10 | 2004-06-30 | Apollo Life Sciences Limited | A method of antibody production |
JP5424640B2 (ja) * | 2005-09-08 | 2014-02-26 | ザ ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン,インコーポレイティド | 免疫源性ペプチドの標的特異的同定方法 |
-
2006
- 2006-09-08 JP JP2008530244A patent/JP5424640B2/ja active Active
- 2006-09-08 WO PCT/US2006/035171 patent/WO2007030771A2/en active Application Filing
- 2006-09-08 CA CA2812794A patent/CA2812794C/en active Active
- 2006-09-08 CA CA002622036A patent/CA2622036A1/en not_active Abandoned
- 2006-09-08 CA CA2812110A patent/CA2812110A1/en not_active Abandoned
- 2006-09-08 EP EP17159896.4A patent/EP3195877A1/en not_active Withdrawn
- 2006-09-08 EP EP06824918.4A patent/EP1934608B8/en active Active
- 2006-09-08 ES ES06824918.4T patent/ES2628308T3/es active Active
-
2011
- 2011-11-24 JP JP2011255687A patent/JP2012072167A/ja active Pending
-
2014
- 2014-07-02 JP JP2014136512A patent/JP2014196341A/ja active Pending
-
2016
- 2016-11-04 JP JP2016216370A patent/JP2017043630A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005007694A1 (ja) * | 2003-07-16 | 2005-01-27 | Green Peptide Co., Ltd. | HER2/neuペプチドおよびその治療上の用途 |
Non-Patent Citations (5)
Title |
---|
BRYAN FISK ET AL.: "Identification of an Immunodominant Peptide ofHER-2/neu Protooncogene Recognized by Ovarian Tumor-sp", J. EXP. MED., vol. Volume 181, JPN7011001762, 1995, pages 2109-2117 * |
COMPUT APPL BIOSCI, vol. 6, no. 2, JPN6013034754, 1990, pages Page.101-105 * |
GAMBOTTO,A. ET AL: "Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-", GENE THER, vol. 7, no. 23, JPN7013002629, 2000, pages 2036 - 40 * |
J MOL GRAPH, vol. 11, no. 3, JPN6013034750, 1993, pages Page.204-210,191-192 * |
MARY L. DISIS ET AL.: "Peptide-based, but not whole protein, vaccines elicit immunity to HER- 2/neu, oncogenic self-protein", THE JOURNAL OF IMMUNOLOGY, vol. Vol 156, Issue 9, JPN6011068127, 1996, pages 3151-3158 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007030771A3 (en) | 2008-11-20 |
JP2012072167A (ja) | 2012-04-12 |
EP1934608B8 (en) | 2017-07-19 |
WO2007030771A2 (en) | 2007-03-15 |
CA2812110A1 (en) | 2007-03-15 |
EP1934608A2 (en) | 2008-06-25 |
EP3195877A1 (en) | 2017-07-26 |
CA2812794C (en) | 2020-02-11 |
JP2017043630A (ja) | 2017-03-02 |
JP5424640B2 (ja) | 2014-02-26 |
WO2007030771A4 (en) | 2008-12-31 |
EP1934608B1 (en) | 2017-03-15 |
CA2622036A1 (en) | 2007-03-15 |
CA2812794A1 (en) | 2007-03-15 |
JP2009508113A (ja) | 2009-02-26 |
EP1934608A4 (en) | 2014-05-14 |
ES2628308T3 (es) | 2017-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Harig et al. | Induction of cytotoxic T-cell responses against immunoglobulin V region–derived peptides modified at human leukocyte antigen–A2 binding residues | |
RU2138512C1 (ru) | Вакцина для профилактики или лечения опосредованной т-клетками патологии или нерегулируемой репликации клонами т-клеток, способ выделения вакцины, способ диагностирования или прогнозирования восприимчивости к ревматоидному артриту или рассеянному склерозу, способ профилактики или лечения ревматоидного артрита или рассеянного склероза и содержащий последовательность sgdqggne пептид, являющийся агентом для обнаружения, профилактики или лечения рассеянного склероза | |
Trojan et al. | Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies | |
US9720000B2 (en) | Targeted identification of immunogenic peptides | |
Verma et al. | Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties | |
CN109970846A (zh) | 一种肿瘤相关抗原XAGE-1b九肽及其应用 | |
US20230098624A1 (en) | Methods and vaccines for inducing immune responses to multiple different mhc molecules | |
US5882654A (en) | Polyvalent melanoma vaccine | |
JP2017043630A (ja) | 免疫源性ペプチドの標的特異的同定方法 | |
JPS62501189A (ja) | 腫瘍↓−胎児に特異的なモノクロナ−ル抗体の調製方法および使用方法 | |
US20180355015A1 (en) | Methods and materials for generating t cells | |
US5840317A (en) | Composition comprising tumor cell lines containing GD2 ganglioside GM2 ganglioside, M-TAA, and either M-urinary antigen or M-fetal antigen | |
EP4284409A2 (en) | Determination and uses of cd8+ t cell epitopes | |
Hos et al. | Bulk,. an den, Ruano, D.,… Ossendorp, F.(2022) | |
CN110016073A (zh) | 一种XAGE-1b九肽及其应用 | |
AU2005309434A1 (en) | Method for identifying and designing immunogenic peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140801 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150929 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151218 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160125 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160329 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161020 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20161107 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20161129 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20170127 |